ERBB2 and breast carcinoma: Consistent with the poor response of HER2-mutant UC patients to the HER kinase inhibitor neratinib as compared to HER2-mutant breast and cervical cancer patients36, the HER2 S310F-mutant cell line UCC14-PDC was significantly less sensitive to neratinib than the HER2-amplified BT-474 breast cancer and HER2 S310F-mutant CVX-4 cervical cancer cell lines.